9. Kết quả ban đầu điều trị Ribociclib kết hợp nội tiết trên bệnh nhân ung thư vú tái phát, di căn có thụ thể nội tiết dương tính

Abstract

The study aims to evaluate the therapeutic efficacy of ribociclib combined with aromatase inhibitors (AI) in patients with recurrent and metastatic breast cancer (mBC) and its side effects. This is a single arm trial involving 57 mBC patients with hormone receptors positive and Her-2/neu negative from May 2021 to August 2023. The average age was 51.5 ± 12.1. 61.4% of patients were in the first line of treatment and 38.6% were in subsequent lines. The average treatment duration was 12.1 ± 5.3 months, with the longest being 23.5 months. The rates of complete response, partial response, stable disease, and progressive disease were 1.8%; 43.8%; 50.8%, and 3.6%, respectively. The median progression-free survival (PFS) was 16.9 months, significantly associated with treatment response (p = 0.006). Common side effects included neutropenia (75.3%), elevated liver enzymes (50.9%), thrombocytopenia (45.5%), and fatigue (33.3%). The ribociclib combined with AI regimen was effective, had acceptable toxicity, and there were no patient death due to the regimen's toxicity.